What if the same types of receptors that allow us to detect smells could also help our immune systems fight cancer?

That's the intriguing question driving new research at Augusta University's Medical College of Georgia, where scientist Marco Orecchioni, PhD, has received a prestigious $3.66 million NIH Director's New Innovator Award to investigate a potentially groundbreaking approach to cancer treatment.

The five-year award, announced in a recent Augusta University Jagwire article, will support Orecchioni's project, Harnessing Myeloid Olfactory Receptors to Reprogram Tumor Immunity.

Orecchioni, an assistant professor in the Department of Pharmacology and Toxicology and researcher with the Immunology Center of Georgia, previously discovered that olfactory receptors, traditionally associated with the sense of smell, are also present on immune cells called macrophages and monocytes.

These receptors can detect chemical signals within the body and influence inflammation and disease progression. Now, his team wants to determine whether they can also influence how immune cells respond to cancer.

Could These Receptors Help Fight Melanoma?

The research will focus on melanoma, investigating whether olfactory receptors can shift immune cells toward fighting tumors rather than supporting their growth.

The project will also explore whether these receptors influence patients' responses to immunotherapy, potentially identifying new targets for cancer treatment.

Orecchioni explained the promise of the research:

"We have preliminary data suggesting that one olfactory receptor may help drive beneficial immune responses against melanoma."

The NIH Director's New Innovator Award recognizes exceptionally creative, high-impact research that challenges conventional scientific approaches.

Klaus Ley, MD, founding co-director of the Immunology Center of Georgia, emphasized the significance of the recognition.

"This is an amazing achievement because very few scientists receive a DP2 award."

Since joining Augusta University in 2023, Orecchioni has earned recognition for his work in immunology, inflammation and cardiovascular disease. His research now extends those discoveries into cancer biology, opening an exciting new direction in understanding how the immune system interacts with tumors.

While the research is still in its early stages, its potential implications for melanoma and immunotherapy make it an important area to watch.

For journalists covering cancer research, immunotherapy, innovative medical discoveries and the future of precision medicine, Orecchioni offers a fascinating perspective on an unconventional approach to fighting cancer.

If you're interested in speaking with Dr. Marco Orecchioni about cancer immunotherapy, melanoma, immune cell biology and his NIH-funded research, contact AU's External Communications Team mediarelations@augusta.edu to arrange an interview today.